9th Annual CAR-TCR Summit (U.S.)
Cell and gene therapy manufacturing holds transformative potential for disease treatment, yet navigating the complexities of autologous and allogeneic cell therapy trials on a global scale presents unique challenges. The journey is often lengthy, costly, and fraught with high failure risks. For biotech firms, especially those operating with finite resources, orchestrating successful cell therapy trials demands strategic planning and expertise.
At Syneos Health, we specialize in bridging these gaps for emerging biotech companies. Our focus extends to key areas:
- Effective Trial Setup for Biotechs: Understanding the nuances of autologous and allogeneic cell therapy, we guide biotechs on how to efficiently organize cell therapy trials.
- Insightful Learnings and Solutions: Drawing from our extensive experience, we share the challenges encountered in the global landscape of cell therapy and distill our main lessons into actionable strategies.
- Partnering with the Right Partner: Navigating the global network, we offer insights into selecting a partner that aligns with your project's specific needs in the dynamic field of cell therapy.
Meet with Us
Join us at the 9th Annual CAR-T Summit to explore how our collective wisdom and insights can be harnessed to tailor solutions to the specific requirements of your trial. We are committed to ensuring the safety and efficacy of each study, keeping patient welfare at the forefront of our efforts.
Our Attendees
Abhi Gupta, Senior Vice President & Head of Cell and Gene Therapy, Syneos Health
Abhi Gupta joined Syneos Health in April 2023 as Senior Vice President, Head of Cell and Gene Therapy. In his role, he drives the development and operationalization of strategic clinical and commercial solutions that accelerate the impact of life-changing genetic medicines for Syneos Health customers and their patients. Prior to Syneos Health, Abhi held various leadership and scientific positions at Pfizer, Regeneron, Citigroup, BMS, and Johnson & Johnson. He is passionate about improving the real-world life experiences of genetic medicine patients and their families and overcoming the pressing challenges of cell and gene therapy research.
Jane K. Bentley, PhD, Vice President, Therapeutic Strategy & Innovation, Oncology and Hematology, Syneos Health
Jane is a distinguished professional in the pharmaceutical industry with over 35 years of experience in oncology drug development. Since May 2016, Jane has been with Syneos Health, where she is passionate about driving strategic innovation in oncology. Her work involves collaborating closely with clients and internal teams to develop and implement solutions-based approaches to drug development, ensuring that new therapies are developed efficiently and effectively. Jane's leadership extends to spearheading cross-functional innovation initiatives, focusing on the patient voice, cell and gene therapy, and rare disease, underlining her dedication to incorporating patient perspectives and addressing the challenges of complex treatments.
Contenu apparenté
Vous voulez en savoir plus? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
A Holistic Approach to Genetic Medicines is Next for the Life Science Industry
Exploring an Expedited Regulatory Pathway for Cell and Gene Therapies
Cell and Gene Therapy Sponsors Must Overcome Unique Hurdles to Realize Promise to Patients
Strategies for Small Biotech in the Development of Cell Therapy Trials
View more of our insights on Cell & Gene Therapy.
Learn more about our Cell & Gene Therapy expertise.
